Effects of Augmented Renal Clearance on Pharmacokinetic and Pharmacodynamic Properties of Levetiracetam in Subarachnoid Hemorrhage
NCT ID: NCT02866877
Last Updated: 2024-04-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
15 participants
OBSERVATIONAL
2016-01-31
2021-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Short Duration Levetiracetam to Extended Course for Seizure Prophylaxis After aSAH
NCT01137110
A Pharmacokinetic Analysis of Levetiracetam Prophylaxis in Critically Ill Patients With Severe Traumatic Brain Injury
NCT04836481
Optimizing Drug Doses in Critically Ill
NCT02437838
Seizure Prophylaxis With Levetiracetam in Aneurysmal Subarachnoid Hemorrhage - Pilot Study
NCT01935908
Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention
NCT00618436
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Subarachnoid Hemorrhage
Pharmacokinetic modeling
Timed blood draws and urine collections to model drug clearance
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pharmacokinetic modeling
Timed blood draws and urine collections to model drug clearance
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Presentation to University of Colorado Hospital within 48 hours of subarachnoid hemorrhage
* Adults ages 18 to 89 years
* Anticipated length of stay ≥ 48 hours
* Informed consent provided by the patient or patient's designated medical proxy
Exclusion Criteria
* Patients receiving renal replacement therapy
* Brain death or imminent brain death expected ≤48 hours
* Patient with history of nephrectomy or renal transplant
18 Years
89 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Colorado, Denver
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Edward T Van Matre, PharmD
Role: PRINCIPAL_INVESTIGATOR
University of Colorado School of Pharmacy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Colorado Hospital
Aurora, Colorado, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15-1823
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.